Clinical trials
Chronic Graft Versus Host Disease clinical trials
Below are recruiting chronic graft versus host disease clinical trials, each written for real people, not researchers. We’re tracking 69 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07127926RecruitingPhase 1
Belumosudil pill vs crushed pill study for chronic GVHD
This trial tests whether crushing belumosudil tablets changes how the drug works in people with chronic graft-versus-host-disease (GVHD), a complication after a stem cell transplant. It helps doctors know if taking crushed pills is as effective as whole tablets.
Houston, TexasAges 18 years+ - NCT07776210RecruitingPhase 3
Eye drops for chronic dry eye after stem cell transplant
This trial tests an eye drop solution for people with chronic dry eye caused by graft-versus-host disease after a stem cell transplant. It aims to see if the drops can reduce eye discomfort and improve the eye surface.
Beverly Hills, CaliforniaAges 18 years+ - NCT06300320RecruitingPhase 2
TQ05105 for chronic graft-versus-host disease
This trial is testing an investigational drug called TQ05105 for people with moderate to severe chronic graft-versus-host disease (GVHD) after a stem cell transplant. It may offer a new treatment option if current therapies are not working well enough.
Hefei, AnhuiAges 18–70 - NCT07124078RecruitingPhase 2
Study of axatilimab for young people with chronic graft-versus-host disease
This study tests a new drug called axatilimab for children and teens with chronic graft-versus-host disease (cGVHD) that hasn't improved with standard treatments. The goal is to see if axatilimab works better than the usual care options. Participants will be randomly assigned to receive either axatilimab or one of several standard treatments.
Duarte, CaliforniaAges 2–17 - NCT07166848Enrolling by invitation
Electrical stimulation study for dry eye from graft vs. host disease
This trial tests if gentle electrical stimulation around the eye can help relieve dry eye symptoms caused by chronic graft versus host disease (a complication after a stem cell or bone marrow transplant). It is for people with moderate to severe dry eye who have not had recent eye surgeries or certain other eye problems.
Boston, MassachusettsAges 18–75 - NCT07246031RecruitingPhase 2
BPC2001 to Prevent Graft-Versus-Host Disease After Stem Cell Transplant
This trial tests a new drug, BPC2001, to see if it can prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) in people receiving a half-matched stem cell transplant from a family donor. It may be an option for adults with certain blood cancers who are planning their first transplant.
Beijing, Beijing MunicipalityAges 18–65 - NCT07011810RecruitingPhase 2
Axatilimab for sclerotic chronic graft-versus-host disease
This study tests a new drug called axatilimab for people with a specific type of chronic graft-versus-host disease (cGVHD) that causes hardening or thickening of the skin or joints. cGVHD is a complication after a stem cell transplant where the donor's immune cells attack your body. The study aims to see if axatilimab can improve these sclerotic symptoms. If you have this condition and it was recently diagnosed (within the last year), you might qualify to participate.
Tampa, FloridaAges 18 years+ - NCT07535008Recruiting
Dental Cleaning to Prevent Graft-Versus-Host Disease
This study tests whether professional dental cleaning after a stem cell transplant can help prevent chronic graft-versus-host disease (GVHD), a condition where transplanted immune cells attack your body. You'll receive dental cleanings and be followed for one year to see if this simple preventive step reduces GVHD complications.
Seattle, WashingtonAges 18 years+ - NCT05470491RecruitingPhase 1/Phase 2
Haploidentical bone marrow transplant with GVHD prevention drugs
This trial tests a reduced-intensity bone marrow transplant from a related donor (haploidentical), using medicines to help prevent a serious complication called GVHD. It is for people with certain blood cancers and aims to improve outcomes by balancing transplant benefit with lower treatment intensity.
Bethesda, MarylandAges 12–120 - NCT06585774RecruitingPhase 3
Axatilimab plus steroids for new chronic GVHD
This study tests a new drug called axatilimab combined with steroids as a first treatment for chronic graft-versus-host disease (GVHD) after a stem cell transplant. It aims to see if this combination helps control symptoms better than steroids alone.
Birmingham, AlabamaAges 12 years+ - NCT06936566RecruitingPhase 2
Ruxolitinib for graft-versus-host disease after transplant
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
Duarte, CaliforniaAges 18 years+ - NCT06343792RecruitingPhase 2
Testing RLS-0071 for steroid-resistant acute graft-versus-host disease
This trial tests a new drug, RLS-0071, for people who are hospitalized with acute graft-versus-host disease that hasn't improved with steroids. It aims to see if the drug is safe and can help control the condition.
Duarte, CaliforniaAges 12 years+ - NCT07070674RecruitingPhase 1
Study of AC-003 for steroid-resistant graft-versus-host disease
This trial tests an experimental capsule (AC-003) for people with graft-versus-host disease (aGVHD) after a stem cell transplant, whose aGVHD did not get better with steroids. The goal is to see if it can help control the condition.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07285889RecruitingPhase 1/Phase 2
Jaktinib as first treatment for acute graft-versus-host disease
This trial tests a new pill called jaktinib for people who develop moderate to severe acute graft-versus-host disease (aGVHD) after a stem cell transplant. The goal is to see if adding jaktinib to standard steroid therapy can better control the disease.
Hangzhou, ZhejiangAges 18 years+ - NCT07253259RecruitingEarly Phase 1
Cell therapy for hard-to-treat chronic graft-versus-host disease
This study tests a new cell therapy called GT729 for people with chronic graft-versus-host disease (cGVHD) that hasn't improved with at least two previous treatments. The therapy is given as an injection and aims to help control the immune system reaction that causes cGVHD.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06186804Enrolling by invitationPhase 2
Study of ABSK021 for chronic graft-versus-host disease
This trial tests an experimental drug (ABSK021) for people with chronic graft-versus-host disease (cGvHD) after a stem cell transplant. It may help if other treatments haven't worked well enough.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06904599RecruitingPhase 2
Testing hCG for acute GVHD after a stem cell transplant
This study tests if a hormone called hCG can help treat moderate-to-severe graft-versus-host disease (GVHD) after a stem cell transplant. It is for adults who have recently developed GVHD and need steroids, but have not been on high-dose steroids for long.
Monterrey, Nuevo LeónAges 18 years+ - NCT06973668RecruitingPhase 2
Comparing drug combos to prevent graft versus host disease after stem cell transplant
This trial tests if a drug combo (cyclophosphamide, sirolimus, and ruxolitinib) works better than another combo (cyclophosphamide, sirolimus, and mycophenolate mofetil) to prevent graft versus host disease in people getting a stem cell transplant for certain blood cancers.
Houston, TexasAges 65–75 - NCT07025538RecruitingPhase 1
Preventing chronic graft-versus-host disease with ruxolitinib
This trial tests whether the drug ruxolitinib, given based on a blood test that predicts risk, can prevent chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It may help people who have a higher risk of developing this complication.
Duarte, CaliforniaAges 18 years+ - NCT07325253RecruitingPhase 2
PET scan study for chronic graft versus host disease
This trial uses a special PET scan to see if we can better understand chronic graft versus host disease (cGVHD), a complication after a stem cell transplant. The study is for people with joint stiffness caused by cGVHD, and it may help doctors find new ways to manage symptoms.
Houston, TexasAges 18 years+ - NCT00092235Recruiting
Understanding chronic graft-versus-host disease outcomes
This study follows patients who have had a stem cell transplant and developed chronic graft-versus-host disease (a condition where transplanted cells attack the body). Researchers will track your symptoms and collect blood samples to understand what affects how well patients do over time.
Bethesda, MarylandAges 1–120 - NCT06660355RecruitingPhase 2
Comparing two medicines for chronic graft-versus-host disease
This trial compares two treatments, ruxolitinib and prednisone, as the first therapy for chronic graft-versus-host disease (cGVHD), a condition where donor cells attack your body after a stem cell transplant. The goal is to see which medicine works better and has fewer side effects.
Miami, FloridaAges 18 years+ - NCT06991361RecruitingPhase 1
Expanded immune cells and low-dose IL-2 for chronic GVHD
This trial tests whether giving special immune cells (regulatory T cells) grown in a lab, along with a low dose of interleukin-2, can help people with chronic graft-versus-host disease (GVHD) that hasn't improved with steroids. GVHD is a complication after a stem cell transplant where donor cells attack the patient's body.
Boston, MassachusettsAges 2 years+ - NCT06247150Recruiting
Study of immune cells in graft-versus-host disease after stem cell transplant
This study looks at immune cells in tissues affected by chronic graft-versus-host disease (cGVHD), a common complication after a stem cell transplant. It aims to better understand the condition, which may lead to better treatments.
PessacAges 18 years+
Hear when a new Chronic Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Chronic Graft Versus Host Disease trials by city
Studies with a site in or near these metro areas.
Chronic Graft Versus Host Disease trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for chronic graft versus host disease?
- Yes. Clin2 currently lists 69 recruiting chronic graft versus host disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic graft versus host disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic graft versus host disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.